Roivant's new 'vant' emerges to advance Bayer lung drug

Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed from Bayer in a deal worth up to $294 million.

United sues FDA to try to block rival’s drug application

In an unusual move, United Therapeutics has filed a lawsuit against the FDA that claims the regulator is sidestepping established norms in allowing rival Liquidia to file

Pfizer’s Revatio flunks paediatric hypertension study

Owlstone signs deal with J&J's Actelion for PH breath test

UK-based Owlstone Medical has signed a deal with Johnson & Johnson’s Actelion unit, to discover and validate a breath-based test for early diagnosis of pulmonary hypertension.<